The proportion of randomized controlled trials that inform clinical practice

被引:18
作者
Hutchinson, Nora [1 ]
Moyer, Hannah [1 ]
Zarin, Deborah A. [2 ]
Kimmelman, Jonathan [1 ]
机构
[1] McGill Univ, Dept Equ Eth & Policy, Studies Translat Eth & Med STREAM, Montreal, PQ, Canada
[2] Brigham & Womens Hosp & Harvard, Multireg Clin Trials Ctr, Boston, MA USA
基金
美国国家卫生研究院;
关键词
clinical trials; informative research; research ethics; None; REDUCING WASTE; INCREASING VALUE;
D O I
10.7554/eLife.79491
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Prior studies suggest that clinical trials are often hampered by problems in design, conduct, and reporting that limit their uptake in clinical practice. We have described 'informativeness' as the ability of a trial to guide clinical, policy, or research decisions. Little is known about the proportion of initiated trials that inform clinical practice. We created a cohort of randomized interventional clinical trials in three disease areas (ischemic heart disease, diabetes mellitus, and lung cancer) that were initiated between January 1, 2009 and December 31, 2010 using . We restricted inclusion to trials aimed at answering a clinical question related to the treatment or prevention of disease. Our primary outcome was the proportion of clinical trials fulfilling four conditions of informativeness: importance of the clinical question, trial design, feasibility, and reporting of results. Our study included 125 clinical trials. The proportion meeting four conditions for informativeness was 26.4% (95% CI 18.9-35.0). Sixty-seven percent of participants were enrolled in informative trials. The proportion of informative trials did not differ significantly between our three disease areas. Our results suggest that the majority of randomized interventional trials designed to guide clinical practice possess features that may compromise their ability to do so. This highlights opportunities to improve the scientific vetting of clinical research.
引用
收藏
页数:14
相关论文
共 39 条
[1]  
[Anonymous], 2020, US PUBLIC LAW 2007B
[2]  
[Anonymous], 2022, UPTODATE IND LEADING
[3]  
[Anonymous], 2022, INFORM TRIALS 436D1E
[4]  
[Anonymous], US PUBLIC LAW 2007A
[5]   Universal Funder Responsibilities That Advance Social Value [J].
Bierer, Barbara E. ;
Strauss, David H. ;
White, Sarah A. ;
Zarin, Deborah A. .
AMERICAN JOURNAL OF BIOETHICS, 2018, 18 (11) :30-32
[6]   Trends in COVID-19 therapeutic clinical trials [J].
Bugin, Kevin ;
Woodcock, Janet .
NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (04) :254-255
[7]   Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials [J].
Carlisle, Benjamin ;
Kimmelman, Jonathan ;
Ramsay, Tim ;
MacKinnon, Nathalie .
CLINICAL TRIALS, 2015, 12 (01) :77-83
[8]   How to increase value and reduce waste when research priorities are set [J].
Chalmers, Iain ;
Bracken, Michael B. ;
Djulbegovic, Ben ;
Garattini, Silvio ;
Grant, Jonathan ;
Guelmezoglu, A. Metin ;
Howells, David W. ;
Ioannidis, John P. A. ;
Oliver, Sandy .
LANCET, 2014, 383 (9912) :156-165
[9]   Increasing value and reducing waste: addressing inaccessible research [J].
Chan, An-Wen ;
Song, Fujian ;
Vickers, Andrew ;
Jefferson, Tom ;
Dickersin, Kay ;
Gotzsche, Peter C. ;
Krumholz, Harlan M. ;
Ghersi, Davina ;
van der Worp, H. Bart .
LANCET, 2014, 383 (9913) :257-266
[10]   Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers [J].
Chen, Ruijun ;
Desai, Nihar R. ;
Ross, Joseph S. ;
Zhang, Weiwei ;
Chau, Katherine H. ;
Wayda, Brian ;
Murugiah, Karthik ;
Lu, Daniel Y. ;
Mittal, Amit ;
Krumholz, Harlan M. .
BMJ-BRITISH MEDICAL JOURNAL, 2016, 352